Economic evaluation has become increasingly important to inform decision makers about how to allocate scare resources, especially with the increasing health care expenditures, the rapid introduction of new medical technologies and the extending role of economic evaluations in health care decision making. Medical innovations are nowadays introduced and diffused in a controlled manner and have to respond to economic criteria. We aim to evaluate the economic value of innovative medical technologies in order to help public and private decision makers to efficiently allocate scare health resources. Our multidisciplinary team provides services, analyses and expertise for several academic, public and private decision makers to efficiently allocate scare health resources, by estimating the relative efficiency of therapeutic and diagnostic interventions (e.g. cost-effectiveness analyses) and by using more innovative methods (e.g. discrete choice experiments, risk-sharing models).
Systematic Reviews & Meta-analyses
Systematic reviews and meta-analyses are key elements of Evidence Based Medicine and Evidence Based Health Care. We have a strong experience in the design and the methodology of systematic reviews and meta-analyses. We use explicit and transparent methods following a standard set of stages and our results are accountable, replicable and updatable. We use the PRISMA statement, which is an Evidence Based minimum set of items for reporting in systematic reviews and meta-analyses. We also use the AMSTAR check list to check the methodological quality of our systematic reviews.
Excellence in biostatistics is a core strength at CHU/ULg. Our talented biostatisticians offer a depth of knowledge and experience in all aspects of clinical research from study design, document preparation for ethic committee review, data analysis, results interpretation to final report.
Our biostatistical expertise has been sharpened over the year in collaboration with biomedical researchers, clinical physicians, public health institutions and pharmaceutical companies. It covers the following domains:
The CHU Laboratory of Cell and Gene Therapy (LTCG) has developed a strong expertise in basic research on in vitro and murine models, in the production of cellular product batches (ATMP) and in running related phase I/II clinical trials.
The LTCG consists of:
- 3 FAMHP-approved tissue banks (hematopoietic cells, cord blood, non-hematopoietic cells) and a GMP facility offering services like cell collection (from patients or normal volunteers), processing, storage and distribution
- R&D unit to transfer innovative cell technologies to the clinic
- ATMP production lab producing and distributing cell products used in patients in the context of approved clinical trials
Contact [email@example.com] us to discuss how these capabilities can forward your projects! We will help you develop tailored solutions.
Our biobank offers a collection of human biological samples (frozen or embedded in paraffin, pathological or non-pathological) with relevant clinical and technical data respecting all ethical, legal and quality requirements.
In addition, our FAMHP-approved tissue bank has a large number of samples of hematopoietic cells, cord blood and non-hematopoietic cells.
Should you request samples, contact us (firstname.lastname@example.org), we will help you to submit your project to the Ethical Committee to get approval and grant you access to the samples.